The estimated Net Worth of James A Datin is at least 494 千$ dollars as of 19 November 2012. Mr. Datin owns over 1,787 units of Orasure Technologies stock worth over 369,219$ and over the last 19 years he sold OSUR stock worth over 0$. In addition, he makes 124,977$ as Independent Director at Orasure Technologies.
James has made over 2 trades of the Orasure Technologies stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 1,787 units of OSUR stock worth 25,179$ on 19 November 2012.
The largest trade he's ever made was buying 1,790 units of Orasure Technologies stock on 23 August 2011 worth over 25,221$. On average, James trades about 85 units every 11 days since 2005. As of 19 November 2012 he still owns at least 86,875 units of Orasure Technologies stock.
You can see the complete history of Mr. Datin stock trades at the bottom of the page.
James Anthony Datin serves as Independent Director of the Company. He currently serves as the President and Chief Executive Officer of BioAgilytix, LLC, a global bioanalytical contract research organization supporting the development of novel therapeutic biologics. Prior to BioAgilytix, from August 2005 to June 2013 Mr. Datin served as the Executive Vice President and Managing Director at Safeguard Scientifics, Inc. (NYSE: SFE), a company focused on providing capital and advice to technology-driven businesses in healthcare, financial services and digital media. Prior to his tenure at Safeguard, Mr. Datin served as the Chief Executive Officer of TouchPoint Solutions, a software solutions provider. Prior to joining TouchPoint, Mr. Datin served in executive positions for Dendrite International and Isuta. Mr. Datin previously served on the Boards of Directors of Clarient (NASDAQ: CLRT), NuPathe Inc. (NASDAQ: PATH), the University City Science Center (Philadelphia) and Laurate Pharma. Mr. Datin earned a B.B.A. at Marshall University, an M.B.A. at the University of New Haven and an Advanced Management Degree at The Wharton School at The University of Pennsylvania.
As the Independent Director of Orasure Technologies, the total compensation of James Datin at Orasure Technologies is 124,977$. There are 11 executives at Orasure Technologies getting paid more, with Stephen Tang having the highest compensation of 2,114,820$.
James Datin is 54, he's been the Independent Director of Orasure Technologies since 2019. There are 8 older and 9 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.
James's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Over the last 21 years, insiders at Orasure Technologies have traded over 21,897,384$ worth of Orasure Technologies stock and bought 196,200 units worth 1,037,188$ . The most active insiders traders include Douglas A Michels、Ronald H Spair、Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 221,123$. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth 194,238$.
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Orasure Technologies executives and other stock owners filed with the SEC include: